07:00 , Sep 14, 2015 |  BC Week In Review  |  Clinical News

Vynfinit vintafolide: Additional Phase IIb data

Endocyte Inc. (NASDAQ:ECYT), West Lafayette, Ind.   Product: Vynfinit vintafolide ( MK-8109 , EC145 )   Business: Cancer   Molecular target: Folate receptor   Description: Folate (vitamin B9) linked to alkaloid chemotherapy agent desacetylvinblastine monohydrazide...
07:00 , Oct 6, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/3 cls AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Baird Christopher Raymond Price target Outperform 39% $32.27 Jefferies Eun Yang Upgrade Buy (from...
07:00 , Oct 6, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/3 cls AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Baird Christopher Raymond Price target Outperform 39% $32.27 Jefferies Eun Yang Upgrade Buy (from...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Clinical News

Vynfinit vintafolide: Additional Phase IIb data

Additional data from the open-label, international Phase IIb TARGET trial in 199 patients with stage IIIb or IV NSCLC showed that Vynfinit plus docetaxel non-significantly improved OS, a secondary endpoint, vs. docetaxel alone (HR=0.88, p=0.2874;...
07:00 , Sep 8, 2014 |  BioCentury  |  Strategy

PI(3)King AbbVie

Erin McCallister, Senior Editor  Job one for Infinity Pharmaceuticals Inc. and new partner AbbVie Inc. will be to carve out a niche for Infinity's duvelisib in chronic lymphocytic leukemia, which is fast becoming a crowded...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Large and in charge

In contrast to the first quarter in which all market cap segments gained ground, only the large caps finished 2Q14 in the black. Gainers outnumbered decliners 20-12 in the over $5 billion segment, which was...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

Merck & Co. Inc, Endocyte deal

Following a comprehensive portfolio assessment, Merck decided to no longer pursue development of vintafolide and returned worldwide rights to the product to Endocyte for all indications. In May, Merck withdrew an MAA from EMA seeking...
07:00 , Jun 23, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 6/20 cls Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Maxim Group Jason Kolbert Price target Buy 26% $8.13 Kolbert raised his target to...
07:00 , May 26, 2014 |  BC Week In Review  |  Clinical News

Folcepri etarfolatide regulatory update

Merck withdrew an MAA from EMA seeking conditional approval of Folcepri etarfolatide, a companion imaging diagnostic for Endocyte's Vynfinit vintafolide, to treat folate receptor-positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin. The companies...
07:00 , May 26, 2014 |  BC Week In Review  |  Clinical News

Neocepri iV folic acid regulatory update

Endocyte and partner Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) announced the withdrawal of an MAA from EMA seeking conditional approval of Neocepri IV folic acid, a companion imaging diagnostic for Endocyte's Vynfinit vintafolide,...